Vertex Pharmaceuticals Stock Plummets to Third Consecutive Day of Decline with $1.749 Billion Trading Volume

On May 7, 2025, Vertex Pharmaceuticals (VRTX) experienced a significant decline, with a trading volume of $1.749 billion, marking a 50.74% decrease from the previous day. The stock price fell by 3.38%, marking the third consecutive day of decline, with a total drop of 13.24% over the past three days.

Vertex Pharmaceuticals' stock price plummeted on Tuesday due to a series of setbacks in the first quarter. These included lower-than-expected sales, slow adoption of two new drugs, and the suspension of a messenger RNA study. The company's total revenues for the quarter fell short of estimates, contributing to the stock's decline.

One of the primary reasons for Vertex's disappointing first-quarter results was the expected revenue decline in Russia. Sales in the country have been negatively impacted by various factors, further exacerbating the company's financial performance.

Vertex Pharmaceuticals' stock continued to fall on Wednesday as Wolfe Research downgraded the cystic fibrosis drugmaker following the release of its first-quarter results. The downgrade added to the negative sentiment surrounding the company, leading to further declines in its stock price.